Pfenex: Biosimilar Enthusiasm Is High

San Diego’s Pfenex Inc. is riding the market’s enthusiasm for biosimilars, molecules that although not considered identical, can be automatically substituted for biologic drugs. Previously considered immune to generic competition,.

Quick update: The IBB – Negative Divergence

iShares Nasdaq Biotechnology (IBB) – Nasdaq As tweeted several time last and early this week, signs of weakness in the IBB Signs of weakness in the $IBB ..Start forming a Bearish.

Chimera Research Group Catalyst Summary for January 2015

At the end of each month Chimera Research Group provides you with a monthly summary of notable catalysts that have been completed during the past month. JANUARY 2015: 1) Bristol-Myers.

Revisiting the Bubble Debate

With this week’s moves in the market and with the JP Morgan Healthcare conference finished, I think its time to bring up the debate again about whether or not biotech.

CBSTZ: New developments for Cubist CVR

A quick update on CBSTZ the Cubist CVR. Today Cubist filed an 8-K notifying CVR holders that it intends to purchase all the CVRs at $0.059225 on February 2, 2015..

Chimera Research Group Catalyst Summary for December 2014

At the end of each month Chimera Research Group provides you with a monthly summary of notable catalysts that have been completed during the past month. DECEMBER 2014: 1) AbbVie.

CBSTZ: a low probability, high impact special situation

This week started with a merger Monday. Cubist Pharmaceuticals agreed to be acquired by Merck & Company for $9.5B including assumption of debt. CBST traded like one would expect on.

BMY – A Bull Flag Breakout or A Head Fake

  Bristol-Myers Squibb Company (BMY)  -NYSE Interesting price action since October 15th, after touching the support line $47.52 and bouncing back to start a new uptrend, we were looking to reach.

Quick Note on GWPH

GWPH has been on one huge rollercoaster. After climbing back from $61 in mid-October to $80 in late November, it has given up 15% in just the last 3 trading.

Quick Survery

We are constantly looking for was to improve Chimera and ensure that everyone is getting value for their money. As part of this process, we are looking for feedback from.

What to Look For at ASH 2014

  The year is nearly over, though it feels like scientific conferences never end. December 6th marks the last big Cancer meeting of the year- then we turn the page to.

ABBV Survey Results [Free Content]

Earlier today on twitter there was a robust debate about the weakness seen in GILD and how this is related to fears on the upcoming competition from ABBV/ENTA. It seemed.

GWPH: A Compelling Story

GW Pharma’s Tuesday morning R&D meeting looked pretty good. Efficacy data were released for 58 patients with full 12-weeks of epidiolex treatment- 40 of whom have been treated for 16-weeks..

Biotech Survey Results- Number 1

This is the first report on what I want to be a fairly regular set of surveys. I want to keep the surveys short to maximize participation as the more.

Sarepta at World Muscle Society: Follow-up

The only new data provided by Sarepta were various measures of lung function, including, including %predicted MIP, MEP, and FVC; all of which demonstrated stabilization through 144 weeks for the.

CNAT – A Quick Chart Update

  Conatus Pharmaceuticals Inc. (CNAT) -Nasdaq CNAT was trading within a downtrend channel since June 16th after reaching the high of $9.90, finding a base around the $6.00 weekly support line.

SRPT- A Squeeze In The Making

  Sarepta Therapeutics, Inc. (SRPT)-Nasdaq   Sarepta is preparing for a busy 4th quarter ahead of the NDA submission as confirmed again by the company’s CEO Chris Garabedian during the Morgan.

SRPT and SAGE: Quick Notes

Nice 36-month Natural history study (or “Pane Study”) in Duchenne published essentially confirming what’s pretty much already known- that boys age 7 and over decline more rapidly than those under.

GW Pharmaceuticals: Quick Update

Investors are waiting impatiently for GW Pharma’s December R&D day. The most sought-after information is updates on the Epidiolex Expanded Access Program in Dravet Syndrome. A previous analysis involved 27.

[Free Report] JNJ Aquires Alios: What This Means For Achillion

Johnson & Johnson announced today it will acquire privately held Alios BioPharma for $1.75 Billion in cash, gaining rights to the mid-stage treatment for infants with respiratory syncytial virus (RSV),.

ECYT Fails to Meet OS Endpoint; Hope Rests on Tubulysin

Endocyte presented much anticipated results from its Phase II TARGET trial of vintafolide in non-small cell lung cancer (NSCLC) at the European Society of Medical Oncology (ESMO) Congress. The study.

Update on previous coverage

  After a while since our last update on these stocks, we wanted to provide an update to our readers on their recent developments and what to expect in the.

[Free Report] SIGA Files for Bankruptcy; NeuroDerm Files for IPO

SIGA Technologies filed for Chapter 11 bankruptcy protection Tuesday as it seeks time to appeal a court order favoring PharmAthene. In an earlier ruling, the Delaware Court of Chancery found.

A closer look at these veterinary stocks: PETX, KIN, PARN

  Animal health (AH) is gaining more and more attention from investors as new companies go public amidst the biotech IPO frenzy. In this report, we’ll focus on three new.

GWPH: Full Throttle Ahead

GW Pharmaceuticals looks to be quite busy in the next few months as a number of trials are initiated. Rapid development along with promising initial results for epilepsy drug Epidiolex.

Merck – Preparing For The Next Move

  Merck & Co. Inc. (MRK) -NYSE   Lately, Merck was under the spot light after Idenix Pharmaceuticals deal, paying $3.85 Billion more than triple Idenix’s market capitalization before the deal.

July 22 Biotech Update

Today and tomorrow are more of the same in that we seem to be in a holding pattern for the large cap earnings. So I will keep this short and.

BMY – In The Inflection Point

  Bristol-Myers Squibb Company (BMY) -NYSE   Bristol-Myers Squibb Co. (BMY) had a wild year, up from the lows of $41.11 in late August 2013 to reach a new 12 years.

CAR-T in the spotlight: Cellectis

  Two weeks ago, Cellectis (ALCLS) and Pfizer (PFE) struck an agreement to develop new chimeric antigen receptor (CAR)-T-based therapies for oncology. Pfizer will pay $80M upfront and up to.


Sunesis (SNSS) The company presented a poster of an MD Anderson-sponsored trial of its investigational drug voseroxin plus decitabine. There was intriguing data with regard to the response rates. 30.

June 11 Biotech Update

Another relatively slow summer day in the market in terms of trading but the sector seemed to outperform the broader market. Even with that marginal outperformance, I would not read.

Browsing 31 / 354 articles